StockData
Invivyd, Inc. logo

Invivyd, Inc. (IVVD) stock

IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3054% below fair value
$0.45−0.02 (-5.23%)

Close on Nov 19, 2026Market cap $131.43MP/E –Yield –

Invivyd net income

Net income is the profit left for shareholders after every expense, interest and tax.

Invivyd's net income for the twelve months ending Jun 30, 2026 was -$107.33M. For fiscal 2025 it was -$52.49M. The highest annual figure on record is -$52.49M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$52.49M–
FY2024Dec 31, 2024-$169.93M–
FY2023Dec 31, 2023-$198.64M–
FY2022Dec 31, 2022-$241.32M–
FY2021Dec 31, 2021-$226.79M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$44.39M–
Q1 FY2026Mar 31, 2026-$41.40M–
Q4 FY2025Dec 31, 2025-$11.07M–
Q3 FY2025Sep 30, 2025-$10.47M–
Q2 FY2025Jun 30, 2025-$14.66M–
Q1 FY2025Mar 31, 2025-$16.29M–
Q4 FY2024Dec 31, 2024-$18.44M–
Q3 FY2024Sep 30, 2024-$60.74M–
Q2 FY2024Jun 30, 2024-$47.25M–
Q1 FY2024Mar 31, 2024-$43.50M–
Q4 FY2023Dec 31, 2023-$73.65M–
Q3 FY2023Sep 30, 2023-$39.44M–
Q2 FY2023Jun 30, 2023-$50.23M–
Q1 FY2023Mar 31, 2023-$35.32M–
Q4 FY2022Dec 31, 2022-$44.57M–
Q3 FY2022Sep 30, 2022-$45.09M–
Q2 FY2022Jun 30, 2022-$50.99M–
Q1 FY2022Mar 31, 2022-$100.67M–
Q4 FY2021Dec 31, 2021-$83.04M–
Q3 FY2021Sep 30, 2021-$60.38M–
Q2 FY2021Jun 30, 2021-$44.67M–
Q1 FY2021Mar 31, 2021-$38.70M–
Q3 FY2020Sep 30, 2020-$48.01M–
Q2 FY2020Jun 30, 2020-$98.00K–

More Invivyd figures

See a number that looks wrong?